Clinical Trials Details

S1320 (Melanoma)

Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093 in BRAFV600E/K Mutant Melanoma

Clinical Trial Categories

  • Cancers and Other Neoplasms